NGM282



NAME OF DRUG : NGM282

ALSO KNOWN AS : NGM282

LABORATORY : NGMBioPHARM

STATUS AND ADVANCEMENT

Type of drug : FGF19 hormon

Clinical trials advancement : Ongoing Phase 2b

Estimated time to market : 92 months.

LABORATORY ABSTRACT ON THE DRUG

Our lead product candidate, NGM282, is an engineered version of the human FGF19 hormone, a primary regulator of bile acid synthesis in the liver. It is also a key signaling molecule in metabolic processes involved in body weight maintenance, including glucose homeostasis and triglyceride regulation. However, overexpression of FGF19 has been shown to promote liver tumor development in transgenic mice. NGM282, accordingly, has been engineered to eliminate the elements of FGF19’s signaling that are associated with those tumorigenic properties while retaining both the FGFR1c- and FGFR4-mediated signaling activities of the native hormone that direct the regulation of metabolism and bile acid synthesis. Thus, we believe that NGM282 presents a unique opportunity to leverage the dual mechanism of FGF19 without the potential tumorigenicity risk, and are pursuing a multi-pronged development program to efficiently evaluate its drug profile and maximize the clinical and commercial potential of NGM282.

HISTORY AND ANALYSIS

FGF19 is known for its links with hepatocarcinoma, we need NGM282 data on long time treatment and a larger population to be positive on this drug !

 

 

RECENT NEWS ON NGM282

2019-10-07 : NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH

2019-03-20 : Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022

2019-01-03 : Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes

2017-04-23 : NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

SOME PUBLICATIONS RELATED WITH NGM282

February 2019 : NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis

December 2017 : Targeting bile acids and lipotoxicity for NASH treatment

July 2017 : Fibroblast growth factor 19, a double-edged sword

January 2017 : Mice species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15 (necessity to monitor HCC risk with FXR agonists )

February 2013 : Dual actions of fibroblast growth factor 19 on lipid metabolism

February 2012 : Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

January 2012 : FGF19 and Cancer

March 2011 : Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH NGM282


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE